Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dong Woon Jeon

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Korean Circulation Journal|February 7, 2022
Ticagrelor Monotherapy After 3-Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk: The Subanalysis From the TICO TrialYong-Joon Lee, Yongsung Suh, Jung-Sun Kim, et al.
Clinical Therapeutics|February 7, 2018
A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled TrialSoon Jun Hong, Han Saem Jeong, Jeong Cheon Ahn, et al.
Korean Circulation Journal|June 3, 2022
Erratum: Correction of Text in the Article "Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI"You-Jeong Ki, Bong Ki Lee, Kyung Woo Park, et al.
JACC. Cardiovascular Interventions|February 19, 2021
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial InfarctionSeung-Jun Lee, Jae Young Cho, Byeong-Keuk Kim, et al.
Korean Circulation Journal|February 7, 2022
Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMIYou-Jeong Ki, Bong Ki Lee, Kyung Woo Park, et al.
Revista Espanola De Cardiologia (English Ed.)|July 22, 2020
Optimal strategy for side branch treatment in patients with left main coronary bifurcation lesionsJihoon Kim, Joo Myung Lee, Taek Kyu Park, et al.
Clinical Therapeutics|September 6, 2020
Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical TrialSang-Hyun Ihm, Woo-Baek Chung, Jong-Min Lee, et al.
Journal of the American College of Cardiology|October 25, 2011
Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trialKyung Woo Park, In-Ho Chae, Do-Sun Lim, et al.
Circulation|December 20, 2011
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter studyHyeon-Cheol Gwon, Joo-Yong Hahn, Kyung Woo Park, et al.
The American Journal of Cardiology|September 14, 2014
Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries)Joo Myung Lee, Kyung Woo Park, Jung-Kyu Han, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Korean Circulation Journal|February 7, 2022
Ticagrelor Monotherapy After 3-Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk: The Subanalysis From the TICO TrialYong-Joon Lee, Yongsung Suh, Jung-Sun Kim, et al.
Clinical Therapeutics|February 7, 2018
A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled TrialSoon Jun Hong, Han Saem Jeong, Jeong Cheon Ahn, et al.
Korean Circulation Journal|June 3, 2022
Erratum: Correction of Text in the Article "Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI"You-Jeong Ki, Bong Ki Lee, Kyung Woo Park, et al.
JACC. Cardiovascular Interventions|February 19, 2021
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial InfarctionSeung-Jun Lee, Jae Young Cho, Byeong-Keuk Kim, et al.
Korean Circulation Journal|February 7, 2022
Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMIYou-Jeong Ki, Bong Ki Lee, Kyung Woo Park, et al.
Revista Espanola De Cardiologia (English Ed.)|July 22, 2020
Optimal strategy for side branch treatment in patients with left main coronary bifurcation lesionsJihoon Kim, Joo Myung Lee, Taek Kyu Park, et al.
Clinical Therapeutics|September 6, 2020
Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical TrialSang-Hyun Ihm, Woo-Baek Chung, Jong-Min Lee, et al.
Journal of the American College of Cardiology|October 25, 2011
Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trialKyung Woo Park, In-Ho Chae, Do-Sun Lim, et al.
Circulation|December 20, 2011
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter studyHyeon-Cheol Gwon, Joo-Yong Hahn, Kyung Woo Park, et al.
The American Journal of Cardiology|September 14, 2014
Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries)Joo Myung Lee, Kyung Woo Park, Jung-Kyu Han, et al.
Pageof 7